Accessible Data Collections for Improved Decision Making in Neuro-Oncology Clinical Trials. Clin Cancer Res. 2023 Mar 20.
View in:
PubMed
Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study. Lancet Haematol. 2023 Mar; 10(3):e203-e212.
View in:
PubMed
Combining Breast Cancer Risk Prediction Models. Cancers (Basel). 2023 Feb 08; 15(4).
View in:
PubMed
Validation of Predictive Analyses for Interim Decisions in Clinical Trials. JCO Precis Oncol. 2023 02; 7:e2200606.
View in:
PubMed
Prospectively shared control data across concurrent randomised clinical trials. Eur J Cancer. 2023 03; 181:18-20.
View in:
PubMed
Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma. Cancer Cell. 2022 11 14; 40(11):1358-1373.e8.
View in:
PubMed
The design and evaluation of hybrid controlled trials that leverage external data and randomization. Nat Commun. 2022 10 02; 13(1):5783.
View in:
PubMed
A validation of models for prediction of pathogenic variants in mismatch repair genes. Genet Med. 2022 10; 24(10):2155-2166.
View in:
PubMed
Novel Clinical Trial Designs in Neuro-Oncology. Neurotherapeutics. 2022 10; 19(6):1844-1854.
View in:
PubMed
Designing and conducting adaptive trials to evaluate interventions in health services and implementation research: practical considerations. BMJ Med. 2022; 1(1).
View in:
PubMed
Genetic subtypes of smoldering multiple myeloma are associated with distinct pathogenic phenotypes and clinical outcomes. Nat Commun. 2022 06 15; 13(1):3449.
View in:
PubMed
Empirical Evaluations of Clinical Trial Designs. JAMA Netw Open. 2022 05 02; 5(5):e2211620.
View in:
PubMed
Clonal hematopoiesis is associated with increased risk of progression of asymptomatic Waldenström macroglobulinemia. Blood Adv. 2022 04 12; 6(7):2230-2235.
View in:
PubMed
Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort study. Lancet Haematol. 2022 May; 9(5):e340-e349.
View in:
PubMed
A Bayesian Multi-Outcome Analysis of Fine Particulate Matter and Cardiorespiratory Hospitalizations. Epidemiology. 2022 03 01; 33(2):176-184.
View in:
PubMed
Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial. NPJ Breast Cancer. 2022 Feb 16; 8(1):18.
View in:
PubMed
The use of external control data for predictions and futility interim analyses in clinical trials. Neuro Oncol. 2022 02 01; 24(2):247-256.
View in:
PubMed
Attenuated response to SARS-CoV-2 vaccine in patients with asymptomatic precursor stages of multiple myeloma and Waldenstrom macroglobulinemia. Cancer Cell. 2022 01 10; 40(1):6-8.
View in:
PubMed
Inference in response-adaptive clinical trials when the enrolled population varies over time. Biometrics. 2023 03; 79(1):381-393.
View in:
PubMed
Leveraging external data in the design and analysis of clinical trials in neuro-oncology. Lancet Oncol. 2021 10; 22(10):e456-e465.
View in:
PubMed
Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial. Trials. 2021 Sep 25; 22(1):651.
View in:
PubMed
Prospective Study Testing a Simplified Paclitaxel Premedication Regimen in Patients with Early Breast Cancer. Oncologist. 2021 11; 26(11):927-933.
View in:
PubMed
Integration of survival data from multiple studies. Biometrics. 2022 12; 78(4):1365-1376.
View in:
PubMed
Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: a phase II and biomarker study. NPJ Breast Cancer. 2021 Aug 25; 7(1):110.
View in:
PubMed
KMDATA: a curated database of reconstructed individual patient-level data from 153 oncology clinical trials. Database (Oxford). 2021 06 26; 2021.
View in:
PubMed
Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial. J Clin Oncol. 2021 07 20; 39(21):2375-2385.
View in:
PubMed
Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab. Cancer Discov. 2021 10; 11(10):2474-2487.
View in:
PubMed
Assessment of Simulated SARS-CoV-2 Infection and Mortality Risk Associated With Radiation Therapy Among Patients in 8 Randomized Clinical Trials. JAMA Netw Open. 2021 03 01; 4(3):e213304.
View in:
PubMed
The effects of releasing early results from ongoing clinical trials. Nat Commun. 2021 02 05; 12(1):801.
View in:
PubMed
Rationale and design of the Novel Uses of adaptive Designs to Guide provider Engagement in Electronic Health Records (NUDGE-EHR) pragmatic adaptive randomized trial: a trial protocol. Implement Sci. 2021 01 07; 16(1):9.
View in:
PubMed
Reply to "Keynote 48: Is it really for everyone?" Oral Oncol. 2021 04; 115:105108.
View in:
PubMed
Meta-Analysis of PD-L1 Expression As a Predictor of Survival After Checkpoint Blockade. JCO Precis Oncol. 2020 Nov; 4:1196-1206.
View in:
PubMed
Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: A Randomized Clinical Trial. JAMA Oncol. 2020 10 01; 6(10):1598-1605.
View in:
PubMed
Oncotype DX testing in node-positive breast cancer strongly impacts chemotherapy use at a comprehensive cancer center. Breast Cancer Res Treat. 2021 Jan; 185(1):215-227.
View in:
PubMed
TBCRC 030: a phase II study of preoperative cisplatin versus paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker. Ann Oncol. 2020 11; 31(11):1518-1525.
View in:
PubMed
Shared and Usable Data From Phase 1 Oncology Trials-An Unmet Need. JAMA Oncol. 2020 07 01; 6(7):980-981.
View in:
PubMed
Optimality of testing procedures for survival data in the nonproportional hazards setting. Biometrics. 2021 06; 77(2):587-598.
View in:
PubMed
Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant. Nat Commun. 2020 06 12; 11(1):2996.
View in:
PubMed
Phase I dose-escalation trial of tucatinib in combination with trastuzumab in patients with HER2-positive breast cancer brain metastases. Ann Oncol. 2020 09; 31(9):1231-1239.
View in:
PubMed
Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression. J Clin Oncol. 2020 07 20; 38(21):2380-2389.
View in:
PubMed
Prediction of Outcomes with a Computational Biology Model in Newly Diagnosed Glioblastoma Patients Treated with Radiation Therapy and Temozolomide. Int J Radiat Oncol Biol Phys. 2020 11 01; 108(3):716-724.
View in:
PubMed
Keynote 48: Is it really for everyone? Oral Oncol. 2020 06; 105:104762.
View in:
PubMed
A Quantitative Framework for Modeling COVID-19 Risk During Adjuvant Therapy Using Published Randomized Trials of Glioblastoma in the Elderly. Neuro Oncol. 2020 Apr 27.
View in:
PubMed
Avoiding Peg-Filgrastim Prophylaxis During the Paclitaxel Portion of the Dose-Dense Doxorubicin-Cyclophosphamide and Paclitaxel Regimen: A Prospective Study. J Clin Oncol. 2020 07 20; 38(21):2390-2397.
View in:
PubMed
Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer. Clin Cancer Res. 2020 06 01; 26(11):2556-2564.
View in:
PubMed
Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis. Clin Cancer Res. 2020 06 15; 26(12):2838-2848.
View in:
PubMed
A Phase II Study of Pembrolizumab in Combination With Palliative Radiotherapy for Hormone Receptor-positive Metastatic Breast Cancer. Clin Breast Cancer. 2020 06; 20(3):238-245.
View in:
PubMed
Identifying ERBB2 Activating Mutations in HER2-Negative Breast Cancer: Clinical Impact of Institute-Wide Genomic Testing and Enrollment in Matched Therapy Trials. JCO Precis Oncol. 2019; 3.
View in:
PubMed
To randomize, or not to randomize, that is the question: using data from prior clinical trials to guide future designs. Neuro Oncol. 2019 10 09; 21(10):1239-1249.
View in:
PubMed
Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myeloma. Am J Hematol. 2019 11; 94(11):1244-1253.
View in:
PubMed
A phase II study of cabozantinib alone or in combination with trastuzumab in breast cancer patients with brain metastases. Breast Cancer Res Treat. 2020 Jan; 179(1):113-123.
View in:
PubMed
Lessons Learned from Deescalation Trials in Favorable Risk HPV-Associated Squamous Cell Head and Neck Cancer-A Perspective on Future Trial Designs. Clin Cancer Res. 2019 12 15; 25(24):7281-7286.
View in:
PubMed
Deviation from the Proportional Hazards Assumption in Randomized Phase 3 Clinical Trials in Oncology: Prevalence, Associated Factors, and Implications. Clin Cancer Res. 2019 11 01; 25(21):6339-6345.
View in:
PubMed
Frequentist operating characteristics of Bayesian optimal designs via simulation. Stat Med. 2019 09 20; 38(21):4026-4039.
View in:
PubMed
Design and Evaluation of an External Control Arm Using Prior Clinical Trials and Real-World Data. Clin Cancer Res. 2019 08 15; 25(16):4993-5001.
View in:
PubMed
Divining responder populations from survival data. Ann Oncol. 2019 06 01; 30(6):1005-1013.
View in:
PubMed
Ribociclib Plus Trastuzumab in Advanced HER2-Positive Breast Cancer: Results of a Phase 1b/2 Trial. Clin Breast Cancer. 2019 12; 19(6):399-404.
View in:
PubMed
Progression Risk Stratification of Asymptomatic Waldenström Macroglobulinemia. J Clin Oncol. 2019 06 01; 37(16):1403-1411.
View in:
PubMed
Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT): A Bayesian Adaptive Platform Trial to Develop Precision Medicines for Patients With Glioblastoma. JCO Precis Oncol. 2019; 3.
View in:
PubMed
Multi-study factor analysis. Biometrics. 2019 03; 75(1):337-346.
View in:
PubMed
Bayesian adaptive design: the future for regional anesthesia trials? Reg Anesth Pain Med. 2019 Mar 02.
View in:
PubMed
Bayesian Adaptive Randomization in Dose-Finding Trials. JAMA Netw Open. 2018 12 07; 1(8):e186075.
View in:
PubMed
Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenstrom macroglobulinemia patients. Blood. 2018 12 13; 132(24):2608-2612.
View in:
PubMed
The clinical trials landscape for glioblastoma: is it adequate to develop new treatments? Neuro Oncol. 2018 07 05; 20(8):1034-1043.
View in:
PubMed
Efficient computation of the joint probability of multiple inherited risk alleles from pedigree data. Genet Epidemiol. 2018 09; 42(6):528-538.
View in:
PubMed
A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma. Br J Haematol. 2018 07; 182(2):222-230.
View in:
PubMed
Adding experimental arms to platform clinical trials: randomization procedures and interim analyses. Biostatistics. 2018 04 01; 19(2):199-215.
View in:
PubMed
Hazards of Hazard Ratios - Deviations from Model Assumptions in Immunotherapy. N Engl J Med. 2018 03 22; 378(12):1158-1159.
View in:
PubMed
Leveraging molecular datasets for biomarker-based clinical trial design in glioblastoma. Neuro Oncol. 2017 Jul 01; 19(7):908-917.
View in:
PubMed
Designing Clinical Trials That Accept New Arms: An Example in Metastatic Breast Cancer. J Clin Oncol. 2017 Sep 20; 35(27):3160-3168.
View in:
PubMed
Feasibility of Ultra-High-Throughput Functional Screening of Melanoma Biopsies for Discovery of Novel Cancer Drug Combinations. Clin Cancer Res. 2017 Aug 15; 23(16):4680-4692.
View in:
PubMed
Bayesian Nonparametric Ordination for the Analysis of Microbial Communities. J Am Stat Assoc. 2017; 112(520):1430-1442.
View in:
PubMed
Bayesian response-adaptive designs for basket trials. Biometrics. 2017 09; 73(3):905-915.
View in:
PubMed
Prognostic role of circulating exosomal miRNAs in multiple myeloma. Blood. 2017 04 27; 129(17):2429-2436.
View in:
PubMed
Bayesian Baskets: A Novel Design for Biomarker-Based Clinical Trials. J Clin Oncol. 2017 Feb 20; 35(6):681-687.
View in:
PubMed
Bayesian adaptive randomization in a clinical trial to identify new regimens for MDR-TB: the endTB trial. Int J Tuberc Lung Dis. 2016 12 01; 20(12):8-12.
View in:
PubMed
A Bayesian response-adaptive trial in tuberculosis: The endTB trial. Clin Trials. 2017 Feb; 14(1):17-28.
View in:
PubMed
Robust lineage reconstruction from high-dimensional single-cell data. Nucleic Acids Res. 2016 08 19; 44(14):e122.
View in:
PubMed
Mitigating Bias in Generalized Linear Mixed Models: The Case for Bayesian Nonparametrics. Stat Sci. 2016 Feb; 31(1):80-95.
View in:
PubMed
Optimal Bayesian adaptive trials when treatment efficacy depends on biomarkers. Biometrics. 2016 06; 72(2):414-21.
View in:
PubMed
On the restricted mean survival time curve in survival analysis. Biometrics. 2016 Mar; 72(1):215-21.
View in:
PubMed
Unbiased estimation for response adaptive clinical trials. Stat Methods Med Res. 2017 Oct; 26(5):2376-2388.
View in:
PubMed
Getting it first versus getting it right: weighing the value of and evidence for progression-free survival as a surrogate endpoint for overall survival in glioblastoma. Neuro Oncol. 2015 May; 17(5):765-6.
View in:
PubMed
Clinical implementation of integrated whole-genome copy number and mutation profiling for glioblastoma. Neuro Oncol. 2015 Oct; 17(10):1344-55.
View in:
PubMed
Combining progression-free survival and overall survival as a novel composite endpoint for glioblastoma trials. Neuro Oncol. 2015 Aug; 17(8):1106-13.
View in:
PubMed
Bifurcation analysis of single-cell gene expression data reveals epigenetic landscape. Proc Natl Acad Sci U S A. 2014 Dec 30; 111(52):E5643-50.
View in:
PubMed
A toolbox for spatiotemporal analysis of voltage-sensitive dye imaging data in brain slices. PLoS One. 2014; 9(9):e108686.
View in:
PubMed
Bayesian designs and the control of frequentist characteristics: a practical solution. Biometrics. 2015 Mar; 71(1):218-226.
View in:
PubMed
Brain Malignancy Steering Committee clinical trials planning workshop: report from the Targeted Therapies Working Group. Neuro Oncol. 2015 Feb; 17(2):180-8.
View in:
PubMed
Subgroup-Based Adaptive (SUBA) Designs for Multi-Arm Biomarker Trials. Stat Biosci. 2016 Jun; 8(1):159-180.
View in:
PubMed
Cross-study validation for the assessment of prediction algorithms. Bioinformatics. 2014 Jun 15; 30(12):i105-12.
View in:
PubMed
Progression-free survival: too much risk, not enough reward? Neuro Oncol. 2014 May; 16(5):615-6.
View in:
PubMed
Risk prediction for late-stage ovarian cancer by meta-analysis of 1525 patient samples. J Natl Cancer Inst. 2014 Apr 03; 106(5).
View in:
PubMed
A comparison of Bayesian adaptive randomization and multi-stage designs for multi-arm clinical trials. Stat Med. 2014 Jun 15; 33(13):2206-21.
View in:
PubMed
Statistical tools and R software for cancer driver probabilities. Methods Mol Biol. 2014; 1101:113-34.
View in:
PubMed
Biomarker-based adaptive trials for patients with glioblastoma--lessons from I-SPY 2. Neuro Oncol. 2013 Aug; 15(8):972-8.
View in:
PubMed
Reply to B. Freidlin et al. J Clin Oncol. 2013 Mar 01; 31(7):970-1.
View in:
PubMed
Defining Predictive Probability Functions for Species Sampling Models. Stat Sci. 2013; 28(2):209-222.
View in:
PubMed
Bayesian adaptive randomized trial design for patients with recurrent glioblastoma. J Clin Oncol. 2012 Sep 10; 30(26):3258-63.
View in:
PubMed
Bayesian enrichment strategies for randomized discontinuation trials. Biometrics. 2012 Mar; 68(1):203-11.
View in:
PubMed
The multivariate beta process and an extension of the Polya tree model. Biometrika. 2011 Mar; 98(1):17-34.
View in:
PubMed